New drug combo tested to slow advanced prostate cancer progression
NCT ID NCT05059236
Summary
This study is testing whether adding a drug called darolutamide to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. Researchers want to see if this combination helps patients live longer without their cancer getting worse. The study involves about 223 men and compares their results to data from a previous study where men received only hormone therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMR - Kansas City
Kansas City, Missouri, 64132, United States
-
Arizona Urology Specialists - Tucson - W Orange Grove
Tucson, Arizona, 85741, United States
-
Associated Medical Professionals of NY Syracuse
Syracuse, New York, 13210, United States
-
Barbara Ann Karmanos Cancer Institute - Detroit Headquarters
Detroit, Michigan, 48201, United States
-
Brigham and Women's Hospital (BWH) - Surgery Urology
Atlanta, Georgia, 30318, United States
-
Carolina Urological Research Center
Myrtle Beach, South Carolina, 29579, United States
-
Columbus Prostate Cancer Center / Radiation Oncology Clinic
Gahanna, Ohio, 43230, United States
-
GU Research Network, LLC - Oncology radiology
Omaha, Nebraska, 68130, United States
-
Houston Methodist Research Institute
Houston, Texas, 77030, United States
-
Inova Schar Cancer Institute (vendor)
Fairfax, Virginia, 22031, United States
-
Lieutenant Colonel Charles S. Kettles VA Medical Center - Oncology
Ann Arbor, Michigan, 48105, United States
-
Michigan Institute of Urology - Troy - Town Center Building
Troy, Michigan, 48084, United States
-
MidLantic Urology - Bala Cynwyd
Bala-Cynwyd, Pennsylvania, 19004, United States
-
Mount Sinai Doctors - Faculty Practice
New York, New York, 10029, United States
-
Mount Sinai Faculty Practice Associates
New York, New York, 10029, United States
-
New Jersey Urology - Clifton
Clifton, New Jersey, 07013, United States
-
New Jersey Urology - Voorhees
Voorhees Township, New Jersey, 08043, United States
-
New Mexico Cancer Center - Albuquerque
Albuquerque, New Mexico, 87109, United States
-
Northwestern Medicine - Urology
Chicago, Illinois, 60611, United States
-
Northwestern University's Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Piedmont Cancer Institute - Atlanta
Atlanta, Georgia, 30318, United States
-
Providence Saint John's Cancer Institute
Santa Monica, California, 90404, United States
-
Spokane Urology PS
Spokane, Washington, 99202, United States
-
The Urology Group - Norwood Surgery Center
Cincinnati, Ohio, 45212, United States
-
Tower Urology
Los Angeles, California, 90048, United States
-
UC San Diego Health - Moores Cancer Center
San Diego, California, 92037, United States
-
UCI Health Center for Urological Care
Orange, California, 92868, United States
-
UM Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
Urology Associates, PC - Nashville
Nashville, Tennessee, 37209, United States
-
Urology Centers of Alabama, PC - Homewood
Homewood, Alabama, 35209, United States
-
XCancer Omaha
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.